A-FABP (adipocyte fatty acid-binding protein), one of the most abundant proteins in adipocytes, plays a key role in obesity-related insulin resistance, inflammation and atherosclerosis in animals. In the present study, we sought to investigate the association of A-FABP with HF (heart failure) in Chinese subjects. Serum A-FABP levels were measured in 252 HF patients and 261 age-, gender-and BMI (body mass index)-matched non-HF subjects. Echocardiography was performed on each patient. The severity of HF was determined by the NYHA (New York Heart Association) classification system. After adjustments for age, gender and BMI, serum A-FABP concentrations in patients with HF were significantly higher than in non-HF patients [11.17 (6.63-19.93) ng/ml compared with 5.67 (3.20-8.87) ng/ml; P < 0.001] and significantly progressed with the NYHA class (P < 0.001). In addition, NT-proBNP (N-terminal pro-brain natriuretic peptide) was independently and positively correlated with A-FABP (standardized β = 0.340, P < 0.001) after adjusting for confounding factors. Each echocardiographic parameter, especially LVEF (left ventricular ejection fraction), was independently associated with A-FABP (all P < 0.05). Multivariate logistic regression analysis demonstrated that A-FABP concentration was an independent risk factor for HF [odds ratio, 6.93 (95 % confidence interval, 2.49-19.30); P < 0.001]. Our results demonstrate that A-FABP is closely associated with HF, and raise the possibility that increased A-FABP may be causally related to the pathogenesis of heart dysfunction in humans.
INTRODUCTION
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ulators that mediate communication between adipose tissue and other organs [2] . A-FABP (adipocyte fatty acid-binding protein, also known as aP2 and FABP4), a member of the lipid chaperone in the FABP family, is the major cytosolic protein of mature adipocytes [3] . It is also highly expressed in macrophages [4] . As a lipid chaperone, this protein is involved in the trafficking of intracellular fatty acids and other lipid signals through interaction with functional targets [5] . Mounting evidence suggests that A-FABP acts at the crossroad between metabolic and inflammatory pathways and plays an important role in the development of insulin resistance, dyslipidaemia and atherosclerosis [6] [7] [8] .
A-FABP is not only an intracellular protein, but also present in circulation [9] . In humans, increased serum A-FABP levels are associated with a greater risk of developing metabolic syndrome and diabetes [10, 11] . A growing body of evidence suggests that A-FABP plays a pathogenic role in the development of CVDs [12] . A genetic variant at the A-FABP locus associated with reduction in A-FABP expression has been reported to reduce the risk of CVDs in a population genetic study [13] . We have recently found that serum A-FABP is closely associated with the presence and severity of coronary artery disease in a cohort of subjects without HF [14] . However, the clinical relevance of A-FABP in HF patients has never been explored to date. Therefore the aim of the present study was to investigate the association of serum A-FABP with heart function and risk of HF in Chinese subjects.
MATERIALS AND METHODS

Study population
The cohort of patients in the present study consisted of 513 subjects who were hospitalized at the Department of Cardiology of the Shanghai Jiao Tong University Affiliated Sixth People's Hospital, between July 2008 and June 2010. We enrolled 252 patients (160 men and 92 women) with acutely decompensated HF. All the patients had HF for at least 6 months and met one of the following inclusion criteria at the time of enrolment: dyspnea at rest or with minimal activity; one or more accompanying signs (respiratory rate 20 breaths/min or pulmonary congestion or pulmonary oedema with rales more than one-third of the lung fields); and one or more objective measures of HF [evidence of congestion or oedema on chest radiography; a pro-BNP (brain natriuretic peptide) level 400 ng/l or an NT-proBNP (N-terminal pro-BNP) level 1000 ng/l]. Subjects with the following conditions were excluded: acute coronary syndrome, coronary bypass surgery and percutaneous coronary intervention within 3 months preceding admission, renal failure (serum creatinine >177 μmol/l), liver dysfunction {ALT (alanine aminotransferase) or AST (aspartate aminotransferase) levels>1.5 times the upper limits of normal [15] }, acute infection, or a history of malignancy. The present study also enrolled 261 age-, gender-and BMI (body mass index)-matched control subjects without HF (non-HF patients: 166 men and 95 women), who were identified with no HF symptoms and admitted to our hospital during the same enrolment period. All patients received a careful history and physical examination.
Written informed consent was obtained from all subjects before participation in the present study, and the study was approved by the ethics committee of the Shanghai Jiao Tong University Affiliated Sixth People's Hospital and complied with the Declaration of Helsinki.
The diagnosis of HF was based on the criteria of the American College of Cardiology/American Heart Association 2005 Guideline Update for the Diagnosis and Management of HF [16] . The severity of HF was categorized by NYHA (New York Heart Association) functional class criteria. HF with normal or mildly abnormal systolic left ventricle function [LVEF (left ventricular ejection fraction) 50%] was defined as HFpEF (HF with preserved LVEF), and LVEF <50 % was defined as HFrEF (HF with reduced LVEF) [17] .
Echocardiography
M-mode and two-dimensional echocardiography were performed within 3 days of hospitalization in all subjects using an Acuson Sequoia 512 ultrasound system (Siemens Medical Solution) with a 3.5 MHz transducer. Echocardiographic determination of the LAD (left atrial dimension, mm), LVDd (left ventricular end-diastolic dimension, mm), LVSd (left ventricular endsystolic dimension, mm), LVEF (%), FS (fractional shortening,%) and PASP (pulmonary artery systolic pressure) were recorded and evaluated by two well-experienced echocardiographers in a blinded manner.
Anthropometric and biochemical assessment
A complete physical examination, including a measurement of height, weight and BP (blood pressure), was performed on each subject. BMI (body mass index) was calculated as weight/height 2 (kg/m 2 ). Peripheral venous blood samples were collected after an overnight fast during the first day of hospitalization and were processed immediately for the biochemical analysis of FPG (fasting plasma glucose), 2hPG (2 h postprandial plasma glucose), serum TC (total cholesterol), TAG (triacylglycerol), HDL-c (highdensity lipoprotein cholesterol), LDL-c (low-density lipoprotein cholesterol), creatinine, hsCRP (high-sensitivity C-reactive protein), CK-MB (creatine kinase-MB), cTnI (cardiac troponin I) and NT-proBNP. The serum was separated into aliquots and stored at − 80
• C before simultaneous analysis of A-FABP. Serum A-FABP levels were measured by sandwich ELISA (Antibody and Immunoassay Services, The University of Hong Kong, Hong Kong, China). This assay has been validated in our previous study and was found highly specific to A-FABP and did not cross-react with other members of the FABP family [18] . The intra-and inter-assay variations were 4.1 and 4.5 %, respectively. The limit of detection for the A-FABP assay is 0.39 ng/ml.
Statistical analysis
All analyses were performed using SPSS version 13.0. Results are presented as means + − S.D. for normal distributions, or medians (interquartile range) for skewed variables. Data that were not normally distributed, as determined by the Kolmogorov-Smirnov test, were logarithmically transformed before analysis. The χ 2 test was used to compare categorical variables between groups. Characteristics of subjects between two groups were compared using unpaired Student's t test for normally distributed variables and Mann-Whitney U-test for skewed variables. One-way ANOVA was used to compare serum A-FABP levels in groups according to NYHA classification. The Spearman correlation analysis with Bonferroni adjustment was used to assess the relationship of serum A-FABP with metabolic and echocardiographic parameters. To determine the independent parameters that correlated with A-FABP, the variables that were significantly correlated with serum A-FABP in the univariate analysis (after Bonferroni correction), or biologically related, were tested in a multiple 
RESULTS
Clinical characteristics of the study subjects
The details of the clinical characteristics of the study population including demographic parameters, biochemical characteristics and medications at admission are shown in Table 1 . Compared with the non-HF group, patients with HF had significantly higher levels of FPG, hsCRP, cTnI, CK-MB and NT-proBNP and lower levels of TAG (triacylglycerol) (all P 0.001). For echocardiographic parameters, patients with HF had significantly higher LAD, LVDd, LVSd and PASP, but significantly lower LVEF and FS (all P < 0.001). The proportion of HF patients treated with loop diuretics, spironolactone, ACEI (angiotensin-converting enzyme inhibitor) or ARB (angiotensin receptor blocker) and β-blockers at admission were 80.6, 81.0, 88.5 and 86.5 %, respectively.
Serum A-FABP levels in control subjects and HF patients
In all subjects in the present study, serum A-FABP concentrations were significantly higher in patients with HF than those without HF after adjustment for age, gender and BMI (P < 0.001). Similar results were found when men and women were analysed separately (both P < 0.001). Compared with men, women had significantly higher A-FABP concentrations in both the non-HF and HF groups (both P < 0.001) ( Table 2 and Figure1A) . There were 73 subjects in the non-HF group and 88 in the HF group who had diabetes. We further compared serum A-FABP levels between non-diabetics and diabetics in men and women, respectively. Significant elevated serum A-FABP levels in diabetes were observed only in men without HF (P < 0.05). Similar to the results in all patients, a 2-fold higher level of serum A-FABP in the HF group compared with those in the non-HF group was observed in both diabetic patients [10. According to the aetiology of HF, 48 % of HF patients had ischaemic cardiomyopathy and 52 % had non-ischaemic cardiomyopathy. In addition, 43.9 % of the subjects had HFrEF and 56.1 % had HFpEF. After controlling for age, gender and BMI, there were no significant differences in serum levels of A-FABP between patients with ischaemic cardiomyopathy and non-ischaemic cardiomyopathy when all subjects were analysed (P = 0.394) or when either gender was considered (P = 0.345 for men; P = 0.815 for women). Similarly, no significant differences in A-FABP levels were observed between patients with HFpEF or HFrEF for all subjects adjusted for age, gender and BMI (P = 0.246) as well as for both gender groups (P = 0.161 for men; P = 0.111 for women) ( Table 2) .
A-FABP and the severity of HF
As shown in Figure 1(B) , the serum A-FABP levels in all subjects increased progressively and significantly with the NYHA class after being adjusted for age, gender and BMI (P < 0.001). Serum A-FABP levels in patients with class II [9.93 (5.91-15.61) ng/ml], class III [11.26 (6.64-21.55) ng/ml] and class IV [17.76 (11.51-24.51) ng/ml] were significantly higher than those in the non-HF group (P < 0.001). Patients with class IV also had significantly higher A-FABP levels than those with class II and class III (P < 0.05-0.001). Median A-FABP concentrations for those with class II, III or IV were 7.38, 9.95 and 16.63 ng/ml respectively, in men and 14.85, 17.61 and 21.38 ng/ml respectively in women. A linear and significant trend was also observed in both genders (P < 0.001).
Association of serum A-FABP levels with biochemical and echocardiographic parameters
The relationship between serum A-FABP levels and a cluster of biochemical parameters and echocardiographic indexes were observed. The results are shown in Table 3 . The analysis demonstrated a significant positive association of serum A-FABP level with age, BMI, FPG, hsCRP and NT-proBNP in all subjects (P 0.001). Notably, A-FABP levels significantly correlated with all echocardiographic indexes and showed significantly positive associations with LAD, LVDd, LVSd and PASP, as well as negative associations with LVEF and FS (all P < 0.001). The correlations of A-FABP with creatinine, hsCRP, NT-proBNP and echocardiographic indexes also held true for both men and women.
To determine the parameters that were independently associated with A-FABP, a multivariate stepwise regression analysis was performed. The analysis involved age, gender, BMI, FPG, 2hPG, lipid profile, creatinine, hsCRP and NT-proBNP. As shown in Table 4 , besides gender (women), BMI, FPG and creatinine, NT-proBNP was demonstrated to be independently and positively correlated with A-FABP (P < 0.001). Furthermore, each echocardiographic parameter was shown to be independently correlated with A-FABP after being adjusted for age, gender, BMI, FPG, 2hPG, lipid profile, creatinine and hsCRP (all P < 0.05). 
Multivariate logistic regression analysis showing factors independently associated with HF
In all subjects, multiple logistic regression analysis was performed using the presence of HF as a dependent variable ( Table 5 ). The variables that were different between subjects with and without HF were selected for analysis by multivariate logistic regression. The analysis involved age, systolic BP, FPG, 2hPG, TAG, creatinine, hsCRP, CK-MB, cTnI, NT-proBNP and A-FABP. As a result, NT-proBNP {OR (odds ratio), 16 .58 [95 % CI (confidence interval), 8.13-33.84]; P < 0.001} and A-FABP [OR, 6.93 (95 % CI, 2.49-19.30); P < 0.001] were found to be independent factors for HF. However, other variables were all excluded in the final model.
DISCUSSION
In the present study, we provide the first clinical evidence demonstrating that serum A-FABP levels are elevated in patients with HF, and increased progressively and significantly with the NYHA function class. Furthermore, we found strong associations of serum A-FABP levels with NT-proBNP, a well-established powerful risk marker in HF [19] and with all echocardiographic parameters.
There is substantial experimental and clinical evidence that A-FABP is a possible mediator in the pathogenesis of obesity-related metabolic deterioration including insulin resistance, Type 2 diabetes, the metabolic syndrome and atherosclerosis [5, [9] [10] [11] . In accordance with these studies, we observed independent positive correlation of serum A-FABP with BMI and blood glucose. A growing body of evidence demonstrates that A-FABP is also a key player in inflammation and actively participates in several proinflammatory processes independently of its effects on lipid metabolism [20] . The macrophage is a critical site of A-FABP action, and macrophage-specific A-FABP deficiency leads to reduced activation of NF-κB (nuclear factor κB) and JNK (c-Jun N-terminal kinase), resulting in impaired production of a cluster of inflammatory cytokines, such as TNFα (tumour necrosis factor α), IL (interleukin)-6, MCP-1 (monocyte chemoattractant protein-1) and IL-1β [21, 22] . Conversely, several inflammatory stimuli, such as TLR (Toll-like receptor) ligands, PMA and oxidized LDL, have been shown to cause significantly increased expression of A-FABP in macrophages [4, 22, 23] . Inflammation is an important player in the pathogenesis and progression of HF. Increased proinflammatory cytokines, particularly TNFα, IL-1, IL-6 and soluble CD14, are produced by mononuclear cells and the damaged myocardium. These factors impair myocardial function by inducing apoptosis, necrosis and hypertrophic response in cardiomyocytes [24, 25] . In the Framingham Heart Study, increased CRP, IL-6 and TNFα levels were able to identify asymptomatic older subjects in the community who were at high risk for the future development of HF [26] . In the present study, we observed significantly higher hsCRP levels in HF patients. In addition, hsCRP was found to be positively correlated with A-FABP, which is in accordance with several previous studies [10, 14] . A recent study reported that A-FABP modulates inflammation in macrophages by forming a finely-tuned positive loop between JNK and AP-1 (activator protein-1), which aggravates the pro-inflammatory responses [21] . Therefore, the elevated circulating levels of A-FABP in HF might be the result of systemic inflammation in HF, through which A-FABP in turn exerts a further adverse impact on cardiac function.
Another notable finding of the present study is the significant correlation of A-FABP levels with NT-proBNP and all echocardiographic parameters, especially with LVEF, independent of other confounding factors, thus supporting our hypothesis that A-FABP was closely associated with heart function. We also found a progressive elevation of serum A-FABP levels with NYHA class in that class III and IV patients had 2-and 3-fold higher A-FABP levels than subjects in the non-HF group, further suggesting a relationship between A-FABP and the severity of HF. Moreover, our logistic regression analysis demonstrated that A-FABP is an independent risk factor for HF, suggesting that it may also promote heart dysfunction through its direct action on cardiomyocytes. Indeed, it has recently been reported that A-FABP secreted by human adipocytes into the extracellular medium in vitro is able to directly suppress cardiomyocyte contraction by attenuating intracellular Ca 2 + level in a concentration dependent manner [27] . Epicardial fat has been reported to be able to directly influence myocardial function because of the absence of a fibrous fascial layer between it and the underlying myocardium [28] . Therefore either A-FABP secreted from epicardial fat tissue or circulating A-FABP released from subcutaneous and/or visceral adipose tissue or from macrophages may participate in mediating heart dysfunction in a paracrinal or endocrinal manner. However, the precise molecular mechanism whereby A-FABP suppresses cardiac function remains elusive.
Our present study is limited by the lack of data regarding accurate body fat such as body fat percentage, visceral fat area and subcutaneous fat area, which may help to clarify the associated mechanism between A-FABP and HF. Increased levels of lipolytic stimuli including TNFα, catecholamines and natriuretic peptides in terminal stages of HF, play a major role in lipolysis in adipocytes, which is mediated in part through the interaction of A-FABP with hormone-sensitive lipase in adipocytes [29, 30] . Whether A-FABP contributes to the pathogenesis of HF by modulating lipolysis still needs to be confirmed in future study. Another limitation is that a number of patients have undergone preliminary treatment in the emergency room, and the majority of NYHA IV patients had reverted to classes II and III when they were subsequently admitted. Therefore we cannot exclude the influence of treatments on serum A-FABP levels, and the influence of mixture of patients with re-compensation and acute decompensation on our study results. As the study population included only patients with normal renal function, our results cannot be used to represent all HF patients. In addition, due to a relatively small sample size and cross-sectional nature, the present study did not address the cause-effect relationship between A-FABP and HF. Long-term prospective studies are warranted to further determine whether A-FABP has the same prognostic significance as NT-proBNP.
In conclusion, our present study is the first demonstration that serum concentrations of A-FABP are elevated in HF patients and are associated with the severity of HF. Furthermore, our finding indicates that A-FABP is a significant risk factor for HF. These results raise the possibility that A-FABP plays a causal role in the pathogenesis of HF, and also suggest that A-FABP may represent a promising pharmacological target for the treatment or prevention of CVDs.
CLINICAL PERSPECTIVES
r Obesity is one of the most common risk factors for CVDs.
Several animal-based studies have demonstrated that A-FABP, a fat-derived adipokine, plays an important role in obesityrelated insulin resistance, inflammation and atherosclerosis. A-FABP has been shown to directly suppress cardiomyocyte contraction in vitro; however, the pathophysiological relevance of A-FABP with respect to heart dysfunction remains elusive.
r In the present study, we provide clinical evidence showing that serum levels of A-FABP are significantly elevated in patients with HF and are independently associated with the deterioration of heart function.
r Our findings suggest that A-FABP may be a key mediator linking obesity with its related cardiovascular disorders, and also raise the possibility that A-FABP may serve as a biomarker for early diagnosis of high-risk individuals with heart disease and a potential therapeutic target for cardiac dysfunction.
